Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.39 |
| ▸ | FDPS | P14324 | 10/20 | 0.37 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22355857 | 1.00 | SPHK2 (0.43) | SPHK2SPHK1GGPS1FDPSSMPD1 | |
| SCHEMBL23772149 | 1.00 | SPHK2 (0.43) | SPHK2SPHK1GGPS1FDPSSMPD1 | |
| SCHEMBL28530657 | 0.81 | SPHK2 (0.41) | SPHK2SPHK1GGPS1FDPSSMPD1 | |
| SCHEMBL27569100 | 0.80 | FDPS (0.41) | GGPS1FDPSSMPD1MEN1MAPT | |
| SCHEMBL19352942 | 0.80 | FDPS (0.41) | GGPS1FDPSSMPD1MEN1MAPT | |
| SCHEMBL27573312 | 0.80 | FDPS (0.41) | GGPS1FDPSSMPD1MEN1MAPT | |
| SCHEMBL28846845 | 0.80 | SPHK2 (0.43) | SPHK2SPHK1GGPS1FDPSSMPD1 | |
| SCHEMBL22003046 | 0.78 | SPHK2 (0.38) | SPHK2SPHK1GGPS1FDPSSMPD1 | |
| SCHEMBL24278922 | 0.78 | SPHK2 (0.38) | SPHK2SPHK1GGPS1FDPSSMPD1 | |
| SCHEMBL22569873 | 0.77 | GGPS1 (0.37) | SPHK2SPHK1GGPS1FDPSSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | RTCB, NSUN3, NSUN2 | SPHK2 4047/4885SPHK1 4099/4885GGPS1 1481/4885 |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | SPHK2 4047/4885SPHK1 4099/4885GGPS1 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.